Vertex Pharmaceuticals Statistics

Total Valuation

ETR:VX1 has a market cap or net worth of EUR 116.80 billion. The enterprise value is 108.05 billion.

Market Cap	116.80B
Enterprise Value	108.05B

Important Dates

The next estimated earnings date is Monday, May 5, 2025.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-1.00%
Shares Change (QoQ)	-0.19%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	255.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	8.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 23.79, with an EV/FCF ratio of -141.55.

EV / Earnings	-208.87
EV / Sales	10.62
EV / EBITDA	23.79
EV / EBIT	25.49
EV / FCF	-141.55

Financial Position

The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.11.

Current Ratio	2.69
Quick Ratio	2.17
Debt / Equity	0.11
Debt / EBITDA	0.36
Debt / FCF	-2.21
Interest Coverage	150.08

Financial Efficiency

Return on equity (ROE) is -3.15% and return on invested capital (ROIC) is 15.71%.

Return on Equity (ROE)	-3.15%
Return on Assets (ROA)	12.68%
Return on Invested Capital (ROIC)	15.71%
Return on Capital Employed (ROCE)	24.21%
Revenue Per Employee	1.74M
Profits Per Employee	-84,809
Employee Count	6,100
Asset Turnover	0.49
Inventory Turnover	5.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.98% in the last 52 weeks. The beta is 0.46, so ETR:VX1's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	+16.98%
50-Day Moving Average	450.83
200-Day Moving Average	438.14
Relative Strength Index (RSI)	39.48
Average Volume (20 Days)	150

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.97

Income Statement

In the last 12 months, ETR:VX1 had revenue of EUR 10.64 billion and -517.34 million in losses. Loss per share was -2.01.

Revenue	10.64B
Gross Profit	5.82B
Operating Income	4.44B
Pretax Income	240.03M
Net Income	-517.34M
EBITDA	4.61B
EBIT	4.44B
Loss Per Share	-2.01

Full Income Statement

Balance Sheet

The company has 5.91 billion in cash and 1.69 billion in debt, giving a net cash position of 9.15 billion.

Cash & Cash Equivalents	5.91B
Total Debt	1.69B
Net Cash	9.15B
Net Cash Per Share	n/a
Equity (Book Value)	15.85B
Book Value Per Share	61.69
Working Capital	5.83B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -475.80 million and capital expenditures -287.55 million, giving a free cash flow of -763.35 million.

Operating Cash Flow	-475.80M
Capital Expenditures	-287.55M
Free Cash Flow	-763.35M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 54.67%, with operating and profit margins of 41.67% and -4.86%.

Gross Margin	54.67%
Operating Margin	41.67%
Pretax Margin	2.25%
Profit Margin	-4.86%
EBITDA Margin	43.33%
EBIT Margin	41.67%
FCF Margin	n/a

Dividends & Yields

ETR:VX1 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.00%
Shareholder Yield	1.00%
Earnings Yield	-0.44%
FCF Yield	-0.65%

Stock Splits

The last stock split was on August 24, 2000. It was a forward split with a ratio of 2.

Last Split Date	Aug 24, 2000
Split Type	Forward
Split Ratio	2

Scores

ETR:VX1 has an Altman Z-Score of 13.47.

Altman Z-Score	13.47
Piotroski F-Score	n/a